Philip Morisky
Philip Morisky has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Dmytro Palii
National Pirogov Memorial Medical University
2 shared publications - Iryna G. Paliy
National Pirogov Memorial Medical University
2 shared publications - Oleh Ksenchyn
Vinnytsya National Pirogov Memorial Medical University, Vinnytsia, Ukraine
2 shared publications - Olena Voinalovych
National Pirogov Memorial Medical University
2 shared publications - Alba Ramírez-Sarmiento
Servicio de Neumología, Centro para el Cuidado de la Salud Respiratoria Hospital Internacional de Colombia‐Fundación Cardiovascular de Colombia FCV‐Fundación Universitaria FCV, Floridablanca, Santander, Colombia, and “EMICON” Research Group, Ministerio de Ciencia y Tecnología (MINCIENCIAS) Bogotá Colombia
1 shared publication - Angie Pabón‐Quezada
Center of Excellence in Pulmonary Hypertension, International Hospital of Colombia Cardiovascular Foundation of Colombia Bucaramanga Colombia
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 1149
Assessment of factors influencing medication adherence in patients with Type 2 Diabetes Mellitus in Bengaluru using structural equation modelling
- 8 July 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 1149
Open AccessAssessment of factors influencing medication adherence in patients with Type 2 Diabetes Mellitus in Bengaluru using structural equation modelling
- Open Access
- 26 December 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 4,p. 60-68
Adherence to Treatment in Different Cohorts: Assessment Using the MMAS-8 Questionnaire (Ukrainian version) and Determinants of Compliance in Individuals with HIV Infection and Viral Hepatitis
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome remain one of the leading global health threats. The basis of treatment is a combination antiretroviral therapy, which suppresses viral replication but does not provide complete elimination, therefore, it requires lifelong treatment. Assessment of adherence to treatment in such patients is an important component of the effectiveness of therapy, for which we used the Morisky-8 questionnaire (MMAS-8 – Morisky Medication Adherence Scale-8) that we had previously translated. The objective: to conduct pilot testing of the translated Ukrainian version of the MMAS-8 treatment adherence scale in people with HIV and comparative analysis of the impact of individual factors on treatment adherence in people with HIV and patients infected with hepatitis B (HBV) or C (HCV) virus. Materials and methods. The study involved 62 people with HIV who were receiving outpatient treatment at the MNPE “Clinical Center for Infectious Diseases” of the Vinnytsya Regional Council. All participants completed the MMAS-8 questionnaire independently. In addition to determining the level of treatment adherence, we analysed the impact on adherence to treatment of individual socio-demographic factors, adherence to a healthy lifestyle, the presence of harmful habits, the presence of side effects of medications, and the number of medications/number of tablets taken by the patient per day. Results. In the group of people with HIV, the level of treatment adherence had a negative correlation with smoking (p < 0.001), frequency of alcohol consumption (p < 0.001) and the presence of side effects of medications in the anamnesis (p < 0.001), and a positive correlation with the attitude to a healthy lifestyle (p = 0.05), sports (p = 0.03) and satisfaction with medical care (p = 0.003). During a similar analysis in the group of patients with HBV or HCV infection, a negative correlation of the level of treatment adherence with smoking (p = 0.03) and frequency of alcohol consumption (p = 0.03) was established, and a positive correlation with the attitude to a healthy lifestyle (p = 0.02) and the nature of work (p = 0.004) was found. Conclusions. We found that among the surveyed people with HIV, 51.6% were patients with a high degree of adherence, 22.6% with a medium degree, and 25.8% with a low degree of treatment adherence. Pilot testing of the Ukrainian version of the eight-item MMAS-8 showed sufficient reliability and validity of the specified tool for assessing adherence to treatment in people with HIV, both in clinical practice and in scientific research.
- 26 December 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 4,p. 60-68
Open AccessAdherence to Treatment in Different Cohorts: Assessment Using the MMAS-8 Questionnaire (Ukrainian version) and Determinants of Compliance in Individuals with HIV Infection and Viral Hepatitis
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome remain one of the leading global health threats. The basis of treatment is a combination antiretroviral therapy, which suppresses viral replication but does not provide complete elimination, therefore, it requires lifelong treatment. Assessment of adherence to treatment in such patients is an important component of the effectiveness of therapy, for which we used the Morisky-8 questionnaire (MMAS-8 – Morisky Medication Adherence Scale-8) that we had previously translated. The objective: to conduct pilot testing of the translated Ukrainian version of the MMAS-8 treatment adherence scale in people with HIV and comparative analysis of the impact of individual factors on treatment adherence in people with HIV and patients infected with hepatitis B (HBV) or C (HCV) virus. Materials and methods. The study involved 62 people with HIV who were receiving outpatient treatment at the MNPE “Clinical Center for Infectious Diseases” of the Vinnytsya Regional Council. All participants completed the MMAS-8 questionnaire independently. In addition to determining the level of treatment adherence, we analysed the impact on adherence to treatment of individual socio-demographic factors, adherence to a healthy lifestyle, the presence of harmful habits, the presence of side effects of medications, and the number of medications/number of tablets taken by the patient per day. Results. In the group of people with HIV, the level of treatment adherence had a negative correlation with smoking (p < 0.001), frequency of alcohol consumption (p < 0.001) and the presence of side effects of medications in the anamnesis (p < 0.001), and a positive correlation with the attitude to a healthy lifestyle (p = 0.05), sports (p = 0.03) and satisfaction with medical care (p = 0.003). During a similar analysis in the group of patients with HBV or HCV infection, a negative correlation of the level of treatment adherence with smoking (p = 0.03) and frequency of alcohol consumption (p = 0.03) was established, and a positive correlation with the attitude to a healthy lifestyle (p = 0.02) and the nature of work (p = 0.004) was found. Conclusions. We found that among the surveyed people with HIV, 51.6% were patients with a high degree of adherence, 22.6% with a medium degree, and 25.8% with a low degree of treatment adherence. Pilot testing of the Ukrainian version of the eight-item MMAS-8 showed sufficient reliability and validity of the specified tool for assessing adherence to treatment in people with HIV, both in clinical practice and in scientific research.
- Open Access
- 1 October 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (4) , e70202
Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life‐threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher. Paradoxically, while early detection of PAH is strongly encouraged to preempt irreversible vascular, cardiac, and multisystem damage, treatment remains largely restricted to those already exhibiting symptoms. Patients in NYHA class I, though experiencing pathophysiological progression, are systematically excluded from approved pharmacological therapies. This disjunction represents not only a clinical and ethical conundrum but also a conceptual paradox: why invest in early diagnosis if early treatment is withheld? Emerging evidence on various chronic diseases, including cancer, infectious diseases like HIV and hepatitis, and even other cardiovascular diseases, underscores the benefits of initiating treatment before the onset of symptoms. In contrast, the current approach to PAH inadvertently promotes a nihilistic “wait and see” policy, exposing asymptomatic patients to preventable deterioration. Herein, we call for a reassessment of clinical guidelines, regulatory frameworks, and access policies with the goal of better aligning them with the biological realities of PAH. While we advocate for a paradigm shift toward the inclusion of NYHA class I patients in treatment strategies, we explicitly acknowledge the current limitations of the evidence base and emphasize the need for ongoing, high‐quality research including counterarguments and the practical challenges of early treatments.
- 1 October 2025
- Published by Wiley in Pulmonary Circulation
- Vol. 15 (4) , e70202
Open AccessWhy Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life‐threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher. Paradoxically, while early detection of PAH is strongly encouraged to preempt irreversible vascular, cardiac, and multisystem damage, treatment remains largely restricted to those already exhibiting symptoms. Patients in NYHA class I, though experiencing pathophysiological progression, are systematically excluded from approved pharmacological therapies. This disjunction represents not only a clinical and ethical conundrum but also a conceptual paradox: why invest in early diagnosis if early treatment is withheld? Emerging evidence on various chronic diseases, including cancer, infectious diseases like HIV and hepatitis, and even other cardiovascular diseases, underscores the benefits of initiating treatment before the onset of symptoms. In contrast, the current approach to PAH inadvertently promotes a nihilistic “wait and see” policy, exposing asymptomatic patients to preventable deterioration. Herein, we call for a reassessment of clinical guidelines, regulatory frameworks, and access policies with the goal of better aligning them with the biological realities of PAH. While we advocate for a paradigm shift toward the inclusion of NYHA class I patients in treatment strategies, we explicitly acknowledge the current limitations of the evidence base and emphasize the need for ongoing, high‐quality research including counterarguments and the practical challenges of early treatments.
- Open Access
- 24 September 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 144-149
Adaptation and Validation of the Ukrainian Version of the Morisky Medication Adherence Scale-8 (MMAS-8) in Patients with HBV and HCV Infection
Despite the effective current approaches to the treatment of HBV and HCV infections, maintaining long-term adherence to antiviral drugs in patients is a challenge. The need to assess adherence to treatment requires a simple and effective tool for this, which is the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire, recognized by the researchers from different countries. However, until now, there was no Ukrainian-language version of this questionnaire. The objective: to translate, carry out a cross-cultural adaptation and validation of the Ukrainian version of the MMAS-8 treatment adherence scale. Materials and methods. According to the recommendations of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), we translated and cross-culturally adapted the original English version of the MMAS-8 questionnaire. 60 patients with HBV or HCV infection took part in the pilot testing of the Ukrainian-language version of the MMAS-8 questionnaire, including 46 men and 14 women. The comprehensibility and complexity of the Ukrainian version of the MMAS-8 was assessed using a Likert scale. To calculate the reliability of the Ukrainian-language version of the MMAS-8 questionnaire, a repeated survey (test-retest method) was conducted with an interval of 7 days. Internal consistency of questions was determined using Cronbach’s α coefficient. Results. It was established that among the surveyed patients, 80% had a high degree of adherence to treatment, 18.3% – an average degree, and 1.7% – a low degree of adherence to treatment. The comprehensibility index and the difficulty index of the translated version of the MMAS-8 were 1.0/1.0, respectively. The reliability of the Ukrainian-language version of the MMAS-8 was established with a reliable correlation coefficient between test-retest results (r = 0.89). The internal consistency of the Ukrainian version of the MMAS-8 questionnaire (by Cronbach’s α reliability method) was 0.74 at an acceptable level of > 0.7. Conclusions. During the translation, adaptation and validation of the Ukrainian version of the MMAS-8, the recommendations of the ISPOR guidelines were taken into account, following which it is possible to avoid bias and ensure the maximum semantic and cultural relevance of the questionnaire. The results of the study demonstrate that the Ukrainian-language version of the Morisky Medication Adherence Scale-8 (MMAS-8) is understandable and uncomplicated for patients, a reliable and valid tool for assessing adherence to treatment in patients with HBV and HCV infection both in clinical practice and in scientific research.
- 24 September 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 144-149
Open AccessAdaptation and Validation of the Ukrainian Version of the Morisky Medication Adherence Scale-8 (MMAS-8) in Patients with HBV and HCV Infection
Despite the effective current approaches to the treatment of HBV and HCV infections, maintaining long-term adherence to antiviral drugs in patients is a challenge. The need to assess adherence to treatment requires a simple and effective tool for this, which is the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire, recognized by the researchers from different countries. However, until now, there was no Ukrainian-language version of this questionnaire. The objective: to translate, carry out a cross-cultural adaptation and validation of the Ukrainian version of the MMAS-8 treatment adherence scale. Materials and methods. According to the recommendations of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), we translated and cross-culturally adapted the original English version of the MMAS-8 questionnaire. 60 patients with HBV or HCV infection took part in the pilot testing of the Ukrainian-language version of the MMAS-8 questionnaire, including 46 men and 14 women. The comprehensibility and complexity of the Ukrainian version of the MMAS-8 was assessed using a Likert scale. To calculate the reliability of the Ukrainian-language version of the MMAS-8 questionnaire, a repeated survey (test-retest method) was conducted with an interval of 7 days. Internal consistency of questions was determined using Cronbach’s α coefficient. Results. It was established that among the surveyed patients, 80% had a high degree of adherence to treatment, 18.3% – an average degree, and 1.7% – a low degree of adherence to treatment. The comprehensibility index and the difficulty index of the translated version of the MMAS-8 were 1.0/1.0, respectively. The reliability of the Ukrainian-language version of the MMAS-8 was established with a reliable correlation coefficient between test-retest results (r = 0.89). The internal consistency of the Ukrainian version of the MMAS-8 questionnaire (by Cronbach’s α reliability method) was 0.74 at an acceptable level of > 0.7. Conclusions. During the translation, adaptation and validation of the Ukrainian version of the MMAS-8, the recommendations of the ISPOR guidelines were taken into account, following which it is possible to avoid bias and ensure the maximum semantic and cultural relevance of the questionnaire. The results of the study demonstrate that the Ukrainian-language version of the Morisky Medication Adherence Scale-8 (MMAS-8) is understandable and uncomplicated for patients, a reliable and valid tool for assessing adherence to treatment in patients with HBV and HCV infection both in clinical practice and in scientific research.